cushing syndrome

in review 4 min read Updated 2026-11-19
cushing syndrome

Always exclude exogenous glucocorticoids (oral, inhaled, intra-articular, topical, ritonavir-boosted) first. Confirm endogenous hypercortisolism with two concordant positive screening tests (1-mg overnight DST, ≥2× 24-h UFC, or ≥2× late-night salivary cortisol) before measuring ACTH or ordering imaging. Once ACTH-dependent disease is confirmed, pituitary MRI lesions <6 mm require IPSS, whereas lesions ≥10 mm do not. Never order random cortisol, random ACTH, or an 8-mg DST as a screening test.


who to test (ES 2008)

  • Most discriminatory signs: easy bruising, facial plethora, proximal myopathy, violaceous striae (>1 cm wide, especially abdominal/axillary)
  • Test in:
    • Unusual features for age (e.g., young-onset osteoporosis, vertebral fractures, resistant hypertension)
    • Multiple progressive features compatible with hypercortisolism
    • Every adrenal incidentaloma (for mild autonomous cortisol secretion [MACS] or overt Cushing syndrome)
  • Do not screen unselected patients with isolated obesity, hypertension, or type 2 diabetes
  • Exclude pseudo-Cushing (non-neoplastic hypercortisolism): severe depression, alcohol use disorder, uncontrolled diabetes, severe obesity, pregnancy, acute physiological stress

step 1 — confirm hypercortisolism

Require two concordant abnormal results from the three first-line tests (at least two collections for UFC or LNSC) before localising the source:

testprotocolpositive thresholdkey pitfalls / special populations
1-mg overnight DST1 mg dexamethasone PO at 23:00–24:00; serum cortisol at 08:00–09:00cortisol >50 nmol/Lfalse positive: oral oestrogen (high CBG), CYP3A4 inducers (phenytoin, carbamazepine, rifampin — check serum dexamethasone level), poor absorption; avoid in pregnancy and enzyme-inducing AEDs; preferred in severe CKD and adrenal incidentaloma
24-h urine free cortisol (UFC)≥2 complete 24-h collections (verify urine Cr and volume)>ULN for assaypreferred in pregnancy; false negative if CrCl <60 mL/min; false positive with high urine volume (>5 L/d) or pseudo-Cushing
late-night salivary cortisol (LNSC)≥2 samples at 23:00–24:00 (passive drool or swab)>ULN (typically >4 nmol/L, assay-specific)measures free cortisol (unaffected by oral oestrogen/CBG); unreliable in shift workers, blood contamination, topical hydrocortisone, or smoking/chewing tobacco
  • Never use random serum cortisol, random ACTH, or 8-mg DST to diagnose Cushing syndrome
  • Suspected cyclic Cushing: use repeated LNSC or UFC during symptomatic phases rather than DST; document active hypercortisolism immediately before dynamic testing or IPSS

step 2 — localise the source

Only after biochemical hypercortisolism is confirmed, measure morning plasma ACTH (repeat if borderline):

Confirmed hypercortisolism
 ├── ACTH suppressed (<2 pmol/L) ──► ACTH-independent (adrenal)
 │     └── Dedicated adrenal CT (adenoma, carcinoma, bilateral hyperplasia)
 │
 └── ACTH unsuppressed / elevated (>4–5 pmol/L) ──► ACTH-dependent
       └── Dedicated pituitary MRI (thin-slice, gadolinium)
             ├── Lesion ≥10 mm (+ concordant dynamic testing) ──► Cushing disease (IPSS not required)
             ├── Lesion <6 mm or normal MRI ──► Bilateral IPSS (gold standard to separate pituitary vs ectopic)
             └── Lesion 6–9 mm ──► Expert judgement (IPSS often performed given high incidentaloma rate)
  • Pituitary Society 2021 updates:
    • IPSS (central-to-peripheral ACTH gradient) is the gold standard to differentiate pituitary Cushing disease from ectopic ACTH (e.g., bronchial carcinoid, small-cell lung cancer, pancreatic/thymic NET); never use IPSS to diagnose hypercortisolism (overlaps with healthy controls and pseudo-Cushing), and always verify the patient is actively hypercortisolaemic at the time of IPSS
    • 8-mg high-dose DST is no longer routinely recommended due to poor specificity and frequent discordance; CRH or desmopressin stimulation plus pituitary MRI and thin-slice chest/abdomen/pelvis CT can assist non-invasively when ectopic ACTH is suspected (e.g., male with severe hypokalaemia and markedly elevated UFC)
    • Ectopic ACTH clues: rapid onset, severe proximal myopathy, profound hypokalaemia (cortisol saturates renal 11β-HSD2 and activates mineralocorticoid receptors), marked hyperpigmentation, high ACTH and very high UFC

management and perioperative care (2021 consensus)

  • First-line therapy = surgical resection of the causative lesion by an experienced surgeon:
    • Cushing disease: transsphenoidal resection (remission ~70–85% for microadenomas)
    • Adrenal adenoma: laparoscopic unilateral adrenalectomy (see adrenal incidentaloma for MACS)
    • Ectopic ACTH: resect primary tumour if localised
  • Post-operative adrenal insufficiency: successful resection suppresses the remaining HPA axis — give perioperative glucocorticoid coverage and monitor morning cortisol (post-op nadir <55 nmol/L defines remission, though late recurrence still requires long-term surveillance); taper physiologic hydrocortisone slowly over months until HPA recovery
  • Medical therapy (bridge to surgery in severe hypercortisolism, persistent/recurrent disease, or non-surgical candidates):
    • Adrenal steroidogenesis inhibitors: ketoconazole, metyrapone, osilodrostat (monitor LFTs, QTc, hypokalaemia, adrenal insufficiency)
    • Pituitary-directed (Cushing disease): pasireotide (high risk of hyperglycaemia), cabergoline
    • Glucocorticoid receptor antagonist: mifepristone (blocks cortisol action — cortisol/ACTH remain elevated, so monitor clinically and for hypokalaemia/endometrial thickening)
    • Refractory severe disease: pituitary radiotherapy or bilateral adrenalectomy (monitor for Nelson syndrome — corticotroph tumour progression and hyperpigmentation)
  • Comorbidity and complication prophylaxis:
    • VTE prophylaxis: Cushing syndrome is strongly prothrombotic (risk peaks peri-operatively and persists for weeks post-op); give perioperative pharmacologic VTE prophylaxis (Pituitary Society 2021)
    • Opportunistic infection: consider Pneumocystis jirovecii (PJP) prophylaxis in severe hypercortisolism (markedly elevated UFC)
    • Treat hypertension, hyperglycaemia, hypokalaemia, and osteoporosis aggressively
mild autonomous cortisol secretion (MACS)

An adrenal incidentaloma with 1-mg DST cortisol >50 nmol/L without overt Cushing stigmata is MACS (ESE 2023). It carries excess risk of hypertension, diabetes, and vertebral fractures — manage comorbidities aggressively, consider surgery in selected patients, and always give perioperative stress steroids if resected.

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction cushing syndrome